Stock listing

BOATS:NUVL Nuvalent, Inc. Stock

US listing (BOATS) of Nuvalent, Inc. · home listing NASDAQ:NUVL

Follow Nuvalent, Inc. into a list and get an email when it puts out news.

Nuvalent, Inc. logo
Ticker
BOATS:NUVL
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BOATS
Currency
USD

What changed lately

Latest news

All Nuvalent, Inc. news

Nuvalent, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 114 in all · newest Jun 10, 2026 · oldest 2021

Where Nuvalent, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:NUVL · Home listingNASDAQUnited StatesUSD
BX Swiss:NUVLBX SwissSwitzerlandCHF
BOATS:NUVL · This pageBOATSUnited StatesUSD

Valuation

Statements: 4 quarters to Mar 31, 2026

Enterprise value
No market cap
P/E
No market cap
EV/sales
No market cap
EV/EBITDA
No market cap
Price/book
No market cap
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
Under 6 months of closes

Forecasts

8 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
124.00 USD · Analysts' mean
EPS, year to Dec 2026
-5.50 · 10 analysts
Revenue, year to Dec 2026
10.74M · 10 analysts

Team and board

Officers

OfficerRole
Constantin FestInvestor Relations
Georg Pirmin MeyerChief International Officer

Board

DirectorRole
Christy OligerDirector
Grant BogleDirector
Ron SquarerDirector

Events

QuarterResults
Q1 2026May 7, 2026 · Before open
Q4 2025Feb 26, 2026
Q3 2025Oct 30, 2025 · Before open
Q2 2025Aug 7, 2025 · Before open
Q1 2025May 8, 2025
Q4 2024Feb 27, 2025 · Before open
Q3 2024Nov 12, 2024 · Before open
Q2 2024Aug 8, 2024 · Before open
Q1 2024May 9, 2024 · Before open
Q4 2023Feb 27, 2024 · Before open
All 20 quarters
QuarterResults
Q3 2023Nov 14, 2023 · Before open
Q2 2023Aug 10, 2023 · Before open
Q1 2023May 11, 2023 · Before open
Q4 2022Mar 16, 2023 · Before open
Q3 2022Nov 10, 2022 · Before open
Q2 2022Aug 10, 2022 · Before open
Q1 2022May 12, 2022 · Before open
Q4 2021Mar 29, 2022 · Before open
Q3 2021Nov 10, 2021 · Before open
Q2 2021Sep 8, 2021 · Before open

Open Events

Financings

RaiseDate
Public offering of shares of Class A common stock
Closed: US$500M raised · US$101 a share · J.P. Morgan +3
Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), TD Cowen (co-lead), Cantor (co-lead)
Nov 24, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue0000000
Research and development307.0M217.8M113.2M63.7M35.6M15.4M9.75M
Selling, general and administrative107.3M62.6M36.2M22.4M10.3M1.50M612.0K
Operating income-414.3M-280.4M-149.5M-86.1M-45.8M-16.9M-10.4M
Depreciation and amortization414.3M280.4M23.3M373.0K215.0K2.35M1.45M
EBITDA00-126.2M-85.7M-45.6M-14.6M-8.91M
Interest expense38.3M23.3M4.25M521.0K00
Income before tax-424.8M-260.0M-126.2M-81.9M-46.3M-14.6M-11.8M
Income tax585.0K764.0K-167.9K-8.51M521.0K-2.35M1.45M
Net income-425.4M-260.8M-126.2M-73.3M-46.3M-14.6M-11.8M
Earnings per share, basic-5.85-3.93-2.17-1.48-2.13-0.64-0.24

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents261.7M145.7M335.4M241.8M68.5M10.3M3.02M
Short-term investments1.11B972.6M384.5M230.4M219.6M0
Receivables4.47M3.20M
Current assets1.39B1.13B726.5M478.0M290.6M10.6M3.32M
Total assets1.41B1.14B732.4M482.5M293.8M10.6M3.32M
Accounts payable30.2M5.22M9.27M7.20M2.89M1.25M723.0K
Current liabilities91.2M54.0M31.8M19.5M8.79M4.38M4.35M
Long-term debt2.23M2.17M
Total debt2.23M2.17M
Total liabilities164.4M72.0M31.8M19.5M8.79M42.0M20.6M
Shareholders' equity1.25B1.07B700.6M463.0M285.0M-31.3M-17.3M
Shares outstanding72.7M66.4M58.2M49.7M21.8M22.9M48.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-275.2M-185.1M-99.7M-65.0M-40.0M-14.9M-9.64M
Capital spending0000000
Free cash flow-275.2M-185.1M-99.7M-65.0M-40.0M-14.9M-9.64M
Cash from investing-124.1M-573.5M-143.5M-10.7M-220.0M-220.0M-220.0M
Cash from financing515.3M568.9M336.8M248.9M318.2M22.3M22.3M
Share buybacks387.0K249.8M318.9M
Change in cash116.1M-189.7M93.6M173.3M58.2M7.32M-9.64M

Open Financials

Cap table

Built by 6ix from Nuvalent, Inc.’s releases · as of Nov 24, 2025

Common shares
73,692,987
Fully diluted
73,692,987

Fully diluted

LineShares
Common shares73,692,987

Share count over time

CountShares
Nov 22, 202673,692,987

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Glenmede Trust Co NA269<0.01%US$23,263NewNov 16, 2026
IFP Advisors, Inc10<0.01%US$1,240No changeOct 16, 2026
SHP Wealth Management4<0.01%US$494No changeNov 19, 2026

Funds

HolderSharesOf the companyValueChangeAs of
Vanguard Total Stock Market Index Fund1.75M2.4%US$216M+5,313Jun 30, 2026
iShares Russell 2000 ETF1.38M1.9%US$170M+156KJun 30, 2026
Vanguard Small-Cap Index Fund1.27M1.7%US$156M+268Jun 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund1.18M1.6%US$130M+387KMay 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF807K1.1%US$99.7M−39,539Jun 30, 2026
Vanguard Small-Cap Value Index Fund802K1.1%US$99M−4,369Jun 30, 2026
First Trust Merger Arbitrage Fund717K0.97%US$88.6MNewJun 30, 2026
Select Health Care Portfolio670K0.91%US$74M−90,000May 31, 2026
Vanguard Extended Market Index Fund608K0.82%US$75M+20,239Jun 30, 2026
Nexpoint Merger Arbitrage Fund598K0.81%US$73.9MNewJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
iShares Russell 2000 Growth ETF496K0.67%US$61.3M+87,890Jun 30, 2026
Fidelity Growth Company Fund371K0.50%US$40.9M−1.1MMay 31, 2026
iShares Biotechnology ETF370K0.50%US$45.7M+14,554Jun 30, 2026
Fidelity Advisor Growth Opportunities Fund349K0.47%US$38.5MNo changeMay 31, 2026
BlackRock Health Sciences Opportunities Portfolio316K0.43%US$34.9MNo changeMay 29, 2026
Select Biotechnology Portfolio273K0.37%US$30.2MNo changeMay 31, 2026
Fidelity Extended Market Index Fund268K0.36%US$29.6M−3,497May 31, 2026
Columbia Small Cap Growth Fund265K0.36%US$29.3M−6,592May 31, 2026
Vanguard Russell 2000 Index Fund257K0.35%US$28.4M+9,137May 31, 2026
Schwab U.S. Small-Cap ETF253K0.34%US$27.9M+256May 31, 2026
Invesco Discovery Fund245K0.33%US$27.1M+10,286May 31, 2026
Fidelity Balanced Fund241K0.33%US$26.6M−66,500May 31, 2026
Fidelity Puritan Fund205K0.28%US$22.6MNo changeMay 31, 2026
Vanguard Health Care Index Fund120K0.16%US$13.2M−45May 31, 2026
First Trust Multi-Strategy Fund116K0.16%US$14.3MNewJun 30, 2026
Neuberger Mid Cap Growth Fund107K0.14%US$11.8MNewMay 31, 2026
Fidelity Growth Company K6 Fund105K0.14%US$11.5M−276KMay 31, 2026
Fidelity Total Market Index Fund102K0.14%US$11.3M+4,650May 31, 2026
Master Small Cap Index Series99,0710.13%US$12.2M+17,722Jun 30, 2026
Fidelity Advisor Small Cap Fund84,5000.11%US$9.33MNewMay 31, 2026
Voya Small Cap Growth Fund84,4260.11%US$9.32M+948May 31, 2026
Fidelity Series Total Market Index Fund80,1330.11%US$8.85M+3,173May 31, 2026
iShares Core S&P Total U.S. Stock Market ETF70,2620.10%US$8.68M−1,414Jun 30, 2026
Fidelity Series Growth Company Fund66,7250.09%US$7.37M−299KMay 31, 2026
EQ/2000 Managed Volatility Portfolio58,3500.08%US$7.21M+6,005Jun 30, 2026
Tema Oncology ETF53,7630.07%US$5.93M+4,524May 31, 2026
Fidelity Enhanced Small Cap Core ETF53,7120.07%US$6.63M+5,315Jun 30, 2026
Fidelity Series Large Cap Stock Fund51,1000.07%US$6.31MNo changeJun 30, 2026
Fidelity Small Cap Growth Index Fund50,3550.07%US$6.22M+12,300Jun 30, 2026
Neuberger Small Cap Growth Fund49,7200.07%US$5.49MNewMay 31, 2026
Vanguard Russell 2000 Growth Index Fund47,0220.06%US$5.19M+1,164May 31, 2026
Fidelity Nasdaq Composite Index Fund44,6300.06%US$4.93M+2,443May 31, 2026
Bridge Builder Tax Managed Small/Mid Cap Fund42,6460.06%US$5.27M+23,179Jun 30, 2026
Invesco Dorsey Wright SmallCap Momentum ETF37,5710.05%US$4.15M−10,170May 31, 2026
LVIP State Street Small-Cap Index Fund37,1310.05%US$4.59M+4,400Jun 30, 2026
Multi-Manager Small Cap Equity Strategies Fund34,6930.05%US$3.83M+477May 31, 2026
Small Cap Growth Fund33,0530.04%US$3.65M+997May 31, 2026
EQ/Small Company Index Portfolio31,8500.04%US$3.93M+4,560Jun 30, 2026
BlackRock Advantage Small Cap Core Fund31,1150.04%US$3.43M−4,438May 29, 2026
Schwab U.S. Broad Market ETF30,4190.04%US$3.36M+479May 31, 2026

This page holds 50 of 189 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Pelish Henry E.
Officer: Chief Scientific Officer
Sale2,111USD 123.81US$261KJul 9, 2026
Porter James Richard
Director, Officer: President and CEO
Sale30,000USD 123.72US$3.71MJul 6, 2026
Balcom Alexandra
Officer: Chief Financial Officer
Sale11,430USD 123.58US$1.41MJul 1, 2026
Noci Darlene
Officer: Chief Development Officer
Sale23,000USD 123.59US$2.84MJul 1, 2026
Noci Darlene
Officer: Chief Development Officer
Sale5,500USD 123.51US$679KJun 29, 2026
Noci Darlene
Officer: Chief Development Officer
Sale20,000USD 122.81US$2.46MJun 9, 2026
Porter James Richard
Director, Officer: President and CEO
Sale12,495USD 87.97US$1.1MJun 8, 2026
Porter James Richard
Director, Officer: President and CEO
Sale14,469USD 88.79US$1.28MJun 8, 2026
Porter James Richard
Director, Officer: President and CEO
Sale3,036USD 89.63US$272KJun 8, 2026
Balcom Alexandra
Officer: Chief Financial Officer
Sale960USD 94.87US$91,075Jun 1, 2026
All 50 trades
InsiderTradeSharesPriceValueDate
Balcom Alexandra
Officer: Chief Financial Officer
Sale2,170USD 95.99US$208KJun 1, 2026
Balcom Alexandra
Officer: Chief Financial Officer
Sale900USD 97.68US$87,912Jun 1, 2026
Balcom Alexandra
Officer: Chief Financial Officer
Sale1,200USD 98.57US$118KJun 1, 2026
Balcom Alexandra
Officer: Chief Financial Officer
Sale3,133USD 99.86US$313KJun 1, 2026
Balcom Alexandra
Officer: Chief Financial Officer
Sale2,588USD 100.65US$260KJun 1, 2026
Balcom Alexandra
Officer: Chief Financial Officer
Sale279USD 101.79US$28,399Jun 1, 2026
Balcom Alexandra
Officer: Chief Financial Officer
Sale200USD 103.84US$20,768Jun 1, 2026
Noci Darlene
Officer: Chief Development Officer
Sale1,300USD 106.26US$138KMay 28, 2026
Noci Darlene
Officer: Chief Development Officer
Sale1,422USD 107.33US$153KMay 28, 2026
Noci Darlene
Officer: Chief Development Officer
Sale1,178USD 108.01US$127KMay 28, 2026
Noci Darlene
Officer: Chief Development Officer
Sale1,500USD 109.30US$164KMay 28, 2026
Noci Darlene
Officer: Chief Development Officer
Sale100USD 109.76US$10,976May 28, 2026
Miller Deborah Ann
Officer: Chief Legal Officer
Sale1,401USD 106.32US$149KMay 28, 2026
Miller Deborah Ann
Officer: Chief Legal Officer
Sale1,530USD 107.45US$164KMay 28, 2026
Miller Deborah Ann
Officer: Chief Legal Officer
Sale900USD 108.14US$97,326May 28, 2026
Miller Deborah Ann
Officer: Chief Legal Officer
Sale1,669USD 109.30US$182KMay 28, 2026
Porter James Richard
Director, Officer: President and CEO
Sale1,699USD 98.54US$167KMay 4, 2026
Porter James Richard
Director, Officer: President and CEO
Sale1,408USD 99.77US$140KMay 4, 2026
Porter James Richard
Director, Officer: President and CEO
Sale7,429USD 101.48US$754KMay 4, 2026
Porter James Richard
Director, Officer: President and CEO
Sale17,353USD 102.10US$1.77MMay 4, 2026
Porter James Richard
Director, Officer: President and CEO
Sale2,111USD 102.88US$217KMay 4, 2026
Balcom Alexandra
Officer: Chief Financial Officer
Sale3,872USD 98.42US$381KMay 1, 2026
Balcom Alexandra
Officer: Chief Financial Officer
Sale7,434USD 99.29US$738KMay 1, 2026
Balcom Alexandra
Officer: Chief Financial Officer
Sale124USD 99.97US$12,396May 1, 2026
Miller Deborah Ann
Officer: Chief Legal Officer
Sale4,418USD 99.13US$438KApr 30, 2026
Miller Deborah Ann
Officer: Chief Legal Officer
Sale1,082USD 99.57US$108KApr 30, 2026
Noci Darlene
Officer: Chief Development Officer
Sale4,500USD 99.35US$447KApr 29, 2026
Noci Darlene
Officer: Chief Development Officer
Sale700USD 100.14US$70,098Apr 29, 2026
Noci Darlene
Officer: Chief Development Officer
Sale300USD 101.17US$30,351Apr 29, 2026
Pelish Henry E.
Officer: Chief Scientific Officer
Sale2,193USD 104.27US$229KApr 9, 2026
Pelish Henry E.
Officer: Chief Scientific Officer
Sale900USD 105.00US$94,500Apr 9, 2026
Porter James Richard
Director, Officer: President and CEO
Sale11,354USD 103.21US$1.17MApr 6, 2026
Porter James Richard
Director, Officer: President and CEO
Sale12,425USD 103.78US$1.29MApr 6, 2026
Porter James Richard
Director, Officer: President and CEO
Sale6,121USD 104.78US$641KApr 6, 2026
Porter James Richard
Director, Officer: President and CEO
Sale100USD 105.60US$10,560Apr 6, 2026
Balcom Alexandra
Officer: Chief Financial Officer
Sale3,544USD 104.39US$370KApr 1, 2026
Balcom Alexandra
Officer: Chief Financial Officer
Sale5,417USD 105.30US$570KApr 1, 2026
Balcom Alexandra
Officer: Chief Financial Officer
Sale2,469USD 106.18US$262KApr 1, 2026
Noci Darlene
Officer: Chief Development Officer
Sale2,532USD 97.43US$247KMar 30, 2026
Noci Darlene
Officer: Chief Development Officer
Sale2,968USD 98.13US$291KMar 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
James Flynn
Other companies: Lite Strategy, Inc. (Non-Executive Director · Since at least Oct 31, 2023); Larimar Therapeutics, Inc. (Director · Since at least May 28, 2020); Synlogic Inc (Director · Mar 19, 2024 – Apr 26, 2025 · Past); BiomX Inc. (Director · Mar 15, 2024 – Apr 21, 2025 · Past); RiceBran Technologies (Director · Jan 3, 2024 – Jan 3, 2024 · Past); Oruka Therapeutics, Inc. (Director · Dec 15, 2022 – Jan 30, 2024 · Past); CareMax Inc (Director · Nov 17, 2022 – Nov 17, 2023 · Past); ARS Pharmaceuticals, Inc. (Director · Nov 8, 2022 – Nov 8, 2022 · Past); Da32 Life Science Tech Acquisition Corp (Director · Jul 27, 2021 – Jul 28, 2023 · Past); Oncorus Inc (Director · Oct 1, 2020 – Feb 17, 2021 · Past); Acutus Medical Inc. (Director · Aug 5, 2020 – Jan 27, 2025 · Past); Deerfield Healthcare Technology Acquisitions Corp (Director · Jul 16, 2020 – Jul 21, 2020 · Past); Q32 Bio Inc. (Director · Mar 27, 2018 – Jun 6, 2019 · Past); AdaptHealth Corp. (Director · Feb 15, 2018 – Nov 8, 2019 · Past); Alpine Immune Sciences Inc (Director · Sep 12, 2016 – Sep 12, 2016 · Past); AveXis Inc (Director · Sep 3, 2015 – Feb 10, 2016 · Past)
Director · Since at least Jul 28, 2021
Christy Oliger
Other companies: Zenas BioPharma, Inc. (Director · Since at least Aug 13, 2026); Bicara Therapeutics Inc. (Director · Since at least Jul 28, 2026); LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); Vera Therapeutics, Inc. (Director · Since at least Jun 7, 2024); Replimune Group, Inc. (Director · Since at least Dec 1, 2021); Karyopharm Therapeutics Inc. (Director · Since at least Aug 28, 2020); RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Sierra Oncology Inc (Director · Jun 2, 2021 – Jul 1, 2022 · Past); Reata Pharmaceuticals Inc (Director · Apr 15, 2021 – Sep 26, 2023 · Past)
Director · Since at least Jun 18, 2025
Sapna Srivastava
Other companies: Alumis Inc. (Independent Board Member · Since at least Jun 27, 2024); Aura Biosciences, Inc. (Director · Since at least Oct 28, 2021); Tourmaline Bio Inc. (Director · Since at least May 6, 2021); Innoviva, Inc. (Director · Jan 1, 2023 – Jun 17, 2024 · Past); Social Capital Suvretta Holdings Corp II (Director · Jun 29, 2021 – Jun 29, 2021 · Past); Intellia Therapeutics, Inc. (Chief Financial & Stategy Offr · May 5, 2016 – May 5, 2016 · Past); Medavail Holdings Inc (Director · Feb 8, 2013 – Jan 12, 2015 · Past)
Director · Since at least Jul 28, 2021
Andrew A F Hack
Other companies: Mersana Therapeutics Inc (Director · Since at least Jun 27, 2017); Atea Pharmaceuticals, Inc. (Director · Oct 29, 2020 – Nov 3, 2020 · Past); BCLS Acquisition Corp (Chief Financial Officer, Director · Oct 21, 2020 – Oct 26, 2020 · Past); Dynavax Technologies Corporation (Director · Aug 12, 2019 – Aug 8, 2023 · Past); Allena Pharmaceuticals Inc (Director · Jun 8, 2018 – Nov 17, 2020 · Past); Editas Medicine, Inc. (Chief Financial Officer · Feb 2, 2016 – Feb 4, 2019 · Past)
Director · Jul 28, 2021 – Dec 11, 2024 · Past
Anna Protopapas
Other companies: Mersana Therapeutics Inc (Director · Since at least Jun 27, 2017); Dicerna Pharmaceuticals Inc (Director · Jan 23, 2019 – Jun 3, 2021 · Past); Bioverativ Inc (Director · Feb 28, 2017 – Mar 8, 2018 · Past); Ariad Pharmaceuticals Inc (Director · Feb 1, 2016 – Feb 16, 2017 · Past)
Director · Since at least Mar 30, 2022
Ron Squarer
Other companies: ADC Therapeutics SA (Director · Since at least Jan 2, 2024); Travere Therapeutics, Inc. (Director · Since at least May 14, 2021); Deciphera Pharmaceuticals LLC (Director · Jan 15, 2021 – Jun 11, 2024 · Past)
Director · Since at least Dec 10, 2025
Cameron Wheeler
Other companies: Oncorus Inc (Director · Oct 1, 2020 – Oct 1, 2020 · Past); Q32 Bio Inc. (Director · Mar 27, 2018 – Jun 6, 2019 · Past)
Director · Since at least Jul 28, 2021
Grant Bogle
Other companies: Epizyme Inc (President and CEO, Director · Sep 2, 2019 – Aug 12, 2022 · Past); Tesaro Inc (Sr. VP, Chief Commercial Ofc · Jul 13, 2015 – Jan 22, 2019 · Past)
Director · Since at least Dec 5, 2024
Ron Squarer
Other companies: ADC Therapeutics SA (Chairman · Since at least Jun 3, 2026); Travere Therapeutics, Inc. (Director · Since at least May 21, 2026)
Director · Since at least Dec 10, 2025
Alexandra Balcom
Other companies: Crescent Biopharma, Inc. (Director · Since at least Jun 13, 2025)
Chief Financial Officer · Since at least Jul 28, 2021
All 24 people
PersonSeat
Dwight Gary Gilliland
Other companies: Labcorp Holdings Inc. (Director · Since at least Oct 30, 2017)
Director · Jul 28, 2021 – Jun 12, 2024 · Past
Benjamin LaneSee Remarks · Since at least Mar 16, 2026
Christopher Durant TurnerChief Medical Officer · Since at least Jul 28, 2021
Constantin FestInvestor Relations · Since at least Jun 9, 2026
Darlene NociChief Development Officer · Since at least Jul 28, 2021
Deborah Ann MillerChief Legal Officer · Since at least Jul 28, 2021
Emily ConleyDirector · Feb 2, 2022 – Aug 23, 2024 · Past
Georg Pirmin MeyerChief International Officer · Since at least May 27, 2026
Henry E PelishChief Scientific Officer · Since at least Jul 9, 2024
James Richard PorterPresident and CEO, Director · Since at least Jul 28, 2021
Joseph PearlbergDirector · Since at least Jul 28, 2021
Matthew ShairDirector · Since at least Jul 28, 2021
Michael L MeyersDirector · Since at least Oct 4, 2022
Robert Bowers JacksonDirector · Jul 28, 2021 – Jul 28, 2021 · Past

Open People

Log in to ask 6ix AI your own questions about Nuvalent, Inc.